KRRO: Korro Bio Net earnings per share (EPS TTM)
R&D complexity and stringent FDA oversight create significant barriers for Korro Bio, Inc. (KRRO). The 12-month EPS trend clearly demonstrates these challenges, where the -9.10 mark reflects the current state of earnings. Korro Bio, Inc. maintains its status as a scientific leader in gene therapy while adhering to basic environmental standards for laboratory waste disposal.
Analytical breakdowns for Korro Bio Inc. (KRRO)
- share price and expert price forecast:
- market capitalization information:
- business book valuation details:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Korro Bio, Inc.|KRRO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Korro Bio, Inc|KRRO - Company Total Debt Obligations|Debt to Book Capitalization Ratio Korro Bio, Inc.|KRRO - Company Long-Term Indebtedness|Company Short-Term Debts Korro Bio|Quick Liquidity Indicator korrobio.com
- net income and valuation multiples indicators:
KRRO - Net Financial Result|Expected Profit Korro Bio, Inc.|KRRO - P/E Multiple|Future Price to Earnings Korro Bio, Inc|KRRO - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio, Inc.|KRRO - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Korro Bio|KRRO - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth korrobio.com|KRRO - Earnings per share growth this year|Net earnings per share growth forecast for next year Korro Bio, Inc.
Fundamental company analysis:KRRO - korrobio.com
Earnings per share (EPS TTM) measures the final financial result of Korro Bio, Inc. (KRRO) over a year distributed across the total share issuance, allowing for an assessment of the actual return per single security. By analyzing the rolling 12-month earnings per share trend, an investor can see the impact of OPERA platform costs and the KRRO-110 candidate on the capitalization of Korro Bio, Inc. (KRRO) within the context of its partnership with Novo Nordisk.
Direct competitors
TEM: Net earnings per share for the last 12 months|Earnings per share for the trailing year QGEN (qiagen.com)|IONS: Net earnings per share (EPS TTM)|RGEN (Repligen Corp) - Earnings per share for the last twelve months|RNA (Avidity) - Net earnings per share (EPS TTM)|CRISPR (CRSP) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months GeneDx Holdings Corp. (WGS)|RARE - Net earnings per one share for the last twelve months|Beam Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year SRPT|Twist Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters 10x TXG|Intellia Therapeutics (NTLA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months STOK|BLFS (BioLife Solutions) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Wave Life Sciences Ltd (WVE)|Net earnings per share for the last 12 months MAZE (Maze Tx)|Net earnings per share for the last four quarters Sionna Corp|Earnings per share for the last twelve months Prime Medicine, Inc. PRME|Net earnings per share (EPS TTM) tayshagtx.com TSHA|QURE - Earnings per share for the last twelve months|Earnings per share for the trailing year MGTX (MeiraGTx Holdings)|Regenxbio (RGNX) - Earnings per share for the last twelve months|Solid Corp - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocugen, Inc.|Net earnings per one share for the last twelve months pacb.com PACB|Net earnings per share (EPS TTM) BNTC|Design Therapeutics Inc - Earnings per share for the last 12 months|Earnings per share for the last twelve months Rocket Pharmaceuticals Inc RCKT|FDMT: Earnings per share for the last 12 months|Lexeo - Net earnings per share (EPS TTM)|EDIT - Net earnings per share (EPS TTM)|Silence Therapeutics plc (SLN) - Earnings per share for the last twelve months|ProQR Therapeutics (PRQR) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Codexis Inc|Net earnings per one share for the last twelve months Sangamo BioSciences SGMO|Earnings per share for the last twelve months Nautilus Biotechnology (NAUT)|MGX (metagenomi.co) - Earnings per share for the trailing year|Earnings per share for the last twelve months Precision BioSciences, Inc. DTIL|Earnings per share for the trailing year GBIO|BOLD - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Exicure, Inc.|IMNN (imunon.com) - Net earnings per share for the last 12 months|Phio Pharmaceuticals Corp. - Earnings per share for the trailing year|MBIO (Mustang Bio Inc) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months RNAZ|Net earnings per share (EPS TTM) BNGO|Net earnings per share for the last four quarters Applied DNA Corp|Earnings per share for the last twelve months bluebird bio, Inc. BLUE|ImmunoPrecise Antibodies Ltd (IPA) - Net earnings per one share for the last twelve months|OMGA: Net earnings per share for the last 12 months|Earnings per share for the trailing year OMIC (Singular Genomics Systems, Inc.)|RGLS: Net earnings per share (EPS TTM)|SYRS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Telesis Bio, Inc.|Earnings per share for the last 12 months TCON (traconpharma.com)|Net earnings per share (EPS TTM) UBX
